EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Subretinal Gene Therapy for X-Linked Retinoschisis

Licong Liang, Kaiqin She, Chengda Ren, Rui Li, Meng Liao, Zhiyan Tao, Fanfei Liu, Jing Su, Ming Hu, Yiliu Yang, Xiaoyue Wang, Charlotte L Zhang und 6 weitere

New England Journal of Medicine · 11.06.2026 · 394 (22) · 2223-2234

DOI: 10.1056/nejmoa2515953 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 11.06.2026. Verfasst von Licong Liang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Eye Proteins, Gene Therapy Agents, Genetic Therapy, Genetic Vectors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Eye ProteinsGene Therapy AgentsGenetic TherapyGenetic VectorsRetinoschisisChildChild, PreschoolHumansMaleDependovirusElectroretinographyInjections, IntraocularRetinaTomography, Optical CoherenceVisual AcuityTreatment OutcomeFollow-Up Studies

Substanzen

Eye ProteinsRS1 protein, human

Autor:innen und Institutionen

  • Department of Ophthalmology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Biotherapy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
  • Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
  • State Key Laboratory of Eye Health, National Clinical Center for Ocular Diseases, National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, China.
  • Institute for Advanced Study on Eye Health and Diseases and Clinical Data Science Institute, Wenzhou Medical University, Wenzhou, China.
  • Artificial Intelligence Cross-Disciplinary Research Institute, Macau University of Science and Technology, Macau, China.

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Liang, L., She, K., Ren, C., Li, R., Liao, M., Tao, Z., Liu, F., Su, J., Hu, M., Yang, Y., Wang, X., Zhang, C. L., Bao, L., Chen, Q., Zhang, K., Wei, Y., Yang, Y., & Lu, F. (2026). Subretinal Gene Therapy for X-Linked Retinoschisis. New England Journal of Medicine, 394(22), 2223-2234. https://doi.org/10.1056/nejmoa2515953

Vancouver

Liang L, She K, Ren C, Li R, Liao M, Tao Z, et al. Subretinal Gene Therapy for X-Linked Retinoschisis. New England Journal of Medicine. 2026;394(22):2223-2234. doi:10.1056/nejmoa2515953

BibTeX
@article{Liang2026,
  author = {Liang, Licong and She, Kaiqin and Ren, Chengda and Li, Rui and Liao, Meng and Tao, Zhiyan and Liu, Fanfei and Su, Jing and Hu, Ming and Yang, Yiliu and Wang, Xiaoyue and Zhang, Charlotte L and Bao, Li and Chen, Qin and Zhang, Kang and Wei, Yuquan and Yang, Yang and Lu, Fang},
  title = {Subretinal Gene Therapy for X-Linked Retinoschisis},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {22},
  pages = {2223--2234},
  doi = {10.1056/nejmoa2515953}
}
Kostenlos starten →